The 3rd Annual Proteomic Based Drug Discovery Summit 2027 focuses on harnessing proteomics to accelerate drug development, from hit screening to in vivo translation, and leveraging the proteome to develop more effective therapies.
Key Topics
Enhancing Mass Spectrometry Through Optimized DIA & TMT Workflows to Balance Speed & Sensitivity for Reliable Workflows
Optimizing Proteomics Approaches for Covalent Drug Discovery: Addressing Specificity, Probe Development, & Metabolite Challenges
Unveiling Protein-Protein Interactions: Advancing Protein Complex Studies Through Translational Proteomic for Informing Drug Development
Advancing Proteomic Approaches for the Discovery & Development of Proximity-Based Therapeutics for Improved Molecular Glue Degraders
Advancing a Chemoproteomic Toolkit for Enhance the Discovery of "Ligandable" Residues for Targeting by Small Molecule Drugs
Enhancing Proteomics Workflows: Merging Discovery & Structural Insights to Enhance Drug Discovery & Development
Innovative Approaches to Target Engagement: From CNS-Penetrant Degraders to High- Throughput Proteomic Readouts
Unravel Binding Profiles Through Hydrogen/Deuterium Exchange & Ubiquitin-Specific Proximity Labeling Approaches for Advancing Drug Discovery & Development
